IASO Bio Has Received Clearance from Japan's PMDA to Initiate Clinical Trial for CAR-T Therapy Equecabtagene Autoleucel in Second- or Third-Line Multiple Myeloma ...Middle East

SHANGHAI and NANJING, China and PLEASANTON, Calif., March 24, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for...

Hence then, the article about iaso bio has received clearance from japan s pmda to initiate clinical trial for car t therapy equecabtagene autoleucel in second or third line multiple myeloma was published today ( Tuesday 24/03/2026 - 11:59 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( IASO Bio Has Received Clearance from Japan's PMDA to Initiate Clinical Trial for CAR-T Therapy Equecabtagene Autoleucel in Second- or Third-Line Multiple Myeloma )

Also on site :

• 1989 Career-Defining Classic Written as a Tribute to Elvis Presley Was a No. 1 Hit 36 Years Ago
• Ukraine Spent Big to Shield Energy Industry From Drones. Is the Mideast Next?
• U.S. Skier Lindsey Vonn Announces Personal Update After Several Surgeries